Navigation Links
Abbott's XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
Date:9/21/2009

SAN FRANCISCO, Sept. 21 /PRNewswire-FirstCall/ -- Long-term data presented today from the SPIRIT III pivotal U.S. clinical trial demonstrated that the observed clinical advantages of Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System continued to increase as compared to the TAXUS(R) Express2 Paclitaxel-Eluting Coronary Stent System (TAXUS). At three years, XIENCE V demonstrated a 43 percent reduction in the risk of major adverse cardiac events (MACE) compared to TAXUS (9.1 percent for XIENCE V vs. 15.7 percent for TAXUS, p-value=0.003)*. MACE is an important composite clinical measure of safety and efficacy outcomes for patients, defined as cardiac death, heart attack (myocardial infarction or MI), or ischemia-driven target lesion revascularization (ID-TLR driven by lack of blood supply). The three-year results from the SPIRIT III trial will be presented today by Gregg W. Stone, M.D., professor of medicine at Columbia University Medical Center, during the 2009 Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco.

"The SPIRIT III results clearly demonstrate that at three years, patients continue to benefit from having been treated with the XIENCE V stent rather than the TAXUS stent, with fewer repeat cardiac procedures and fewer heart attacks in patients who received XIENCE V," said Dr. Stone, who is also immediate past chairman of the Cardiovascular Research Foundation, New York; and principal investigator of the SPIRIT III trial.

XIENCE V demonstrated an impressive low rate of very late stent thrombosis (one to three years) with no additional events between two and three years. Per protocol, XIENCE V demonstrated a 0.2 percent** very late stent thrombosis rate compared to 1.0 percent for TAXUS (p-value=0.10) at three years. Per Academic Research Consortium (ARC) definition of definite/probable stent thrombosis, the rate of very
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
2. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
3. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
4. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
5. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
6. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
7. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
8. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
9. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
10. Clinical Genomics Continues Progress in Developing Biomarker Portfolio for Colorectal Cancer Testing
11. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... and MENLO PARK, Calif. , July ... DMPI) ("DelMar" "the company") announced today that the company,s board ... from December 31 to June 30. Accordingly, DelMar will file ... Jeffrey Bacha , president and CEO of ... important step in achieving our goal of obtaining a senior ...
(Date:7/24/2014)... ATLANTA , July 24, 2014  Alimera Sciences, ... company that specializes in the research, development and commercialization ... release its second quarter of fiscal year 2014 financial ... 2014. An investor conference call will follow on the ... The conference call will be hosted by Dan ...
(Date:7/24/2014)... 24, 2014  Perrigo Company (NYSE: PRGO ... AB therapeutic equivalent rating from the U.S. Food and ... Application (NDA) for testosterone gel 1.0%. FDA concluded that ... 1% and can be substituted with the full expectation ... safety profile as AndroGel 1% when used under the ...
Breaking Medicine Technology:DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3Alimera Sciences To Release Second Quarter 2014 Results 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 3
... 2011 Bacterin International Holdings, Inc. (NYSE ... developer of revolutionary bone graft material and anti-microbial coatings ... first quarter ended March 31, 2011.  Since the beginning ... the number of medical facilities in which its products ...
... Technologies Inc. (OTCBB: MDCE), a children,s healthcare service ... children,s health and wellness center. The City of Dongguan ... of choice to establish the Company,s first flagship pediatric ... chosen because of its progressive economics, recording 10.3% GDP ...
Cached Medicine Technology:Bacterin International Holdings, Inc. Reports First Quarter 2011 Financial Results 2Bacterin International Holdings, Inc. Reports First Quarter 2011 Financial Results 3Bacterin International Holdings, Inc. Reports First Quarter 2011 Financial Results 4Bacterin International Holdings, Inc. Reports First Quarter 2011 Financial Results 5Bacterin International Holdings, Inc. Reports First Quarter 2011 Financial Results 6Bacterin International Holdings, Inc. Reports First Quarter 2011 Financial Results 7Bacterin International Holdings, Inc. Reports First Quarter 2011 Financial Results 8Bacterin International Holdings, Inc. Reports First Quarter 2011 Financial Results 9Medical Care Technologies Inc. Selects Geographical Location for Flagship Children's Health Center 2Medical Care Technologies Inc. Selects Geographical Location for Flagship Children's Health Center 3
(Date:7/25/2014)... Las Vegas, NV (PRWEB) July 25, 2014 ... hosting the one day Online Workshop ‘Consciousness is Power’ ... the globe are invited to attend this life transforming ... their consciousness to a higher level. Few days are ... During this workshop, Mahendra Trivedi and Trivedi Masters™ Dahryn ...
(Date:7/25/2014)... Fort Myers, FL (PRWEB) July 25, 2014 ... Apple iPhones, iPods, and iPads. The app provides a ... preventing painful and potentially dangerous sunburns and skin damage. ... about the sights, sounds, and capabilities of iTanSmart. ... by describing the app as a ‘better organized’ and ...
(Date:7/25/2014)... Silver®Care , for the first time in the United ... kill oral bacteria and airborne bacteria from the bathroom that ... the most common and important device in the prevention of ... to constant contamination by bacteria found in the mouth and ... mouth than anywhere else in the human body, and some ...
(Date:7/24/2014)... 2014 A few weeks have passed ... incredible high jump by Inika McPherson is a feat ... the USATF National Championships hosted the best track and ... McPherson, won US Nationals with the 2nd best jump ... for the biggest height over head jump in history. ...
(Date:7/24/2014)... Voted one of the most reliable online dress suppliers ... providing its new and old customers with the latest ... announced its new collection of high end wedding dresses. ... to the latest fashion trends. Additionally, they are now ... As a matter of fact, high end special occasion ...
Breaking Medicine News(10 mins):Health News:Mahendra Trivedi to Host an Online Workshop ‘Consciousness is Power’ 2Health News:Mahendra Trivedi to Host an Online Workshop ‘Consciousness is Power’ 3Health News:iTanSmart® Suntan App by UV Technologies, LLC Gets a ‘Big Thumbs Up’ from New York Times App Smart Columnist, Kit Eaton 2Health News:iTanSmart® Suntan App by UV Technologies, LLC Gets a ‘Big Thumbs Up’ from New York Times App Smart Columnist, Kit Eaton 3Health News:Silver®Care’s New Silver Antibacterial Toothbrushes Naturally Kill Oral Germs 2Health News:Silver®Care’s New Silver Antibacterial Toothbrushes Naturally Kill Oral Germs 3Health News:Setting A New High Jump World Record In Zensah® Compression 2Health News:Setting A New High Jump World Record In Zensah® Compression 3Health News:BellasDress Helps Brides Get High End Wedding Dresses for Their Romantic Weddings 2
... must pass legislation to give FDA needed regulatory ... The following is a,statement by Ron Davis, M.D., ... the U.S. House of Representatives must take a ... ,Family Smoking and,Tobacco Control Act, and giving the ...
... The Los Angeles Jewish Home,s,prestigious new Annenberg School ... second session as one of the only U.S. multi-level,senior-living ... Annenberg School of Nursing offers a full-time program that ... licensure. The,intensive vocational nursing program engages students 40 hours ...
... Researchers at the University of Minnesota have found that cerebral malaria ... survivors. The research is published in the current issue of the ... Malaria is a leading cause ... affects more than 750,000 children a year, is one of the ...
... Available For International Licensing, LAS VEGAS, ... SKVI)( http://www.skinvisible.com, , http://www.invisicare.com ), the developers ... enhances topical skincare products, announces,the successful development ... the,active ingredient avobenzone (Parsol(R) 1789) with Invisicare. ...
... Applauds Chance to Make a Difference, ROSEMONT, Ill., ... Convention confirmed today that the $25,000,offer to Steve Bartman ... online polls, the public says he should appear., ... 3 at the Donald E.,Stephens Convention Center in Rosemont, ...
... allergies such as asthma and hay fever might enjoy a ... New South Wales (UNSW). , In a paper presented at ... with one of these atopic diseases are up to 25 ... Non-Hodgkin Lymphoma (NHL). , The InterLymph Symposium is co-hosted by ...
Cached Medicine News:Health News:Los Angeles Jewish Home's New Annenberg School of Nursing Seeks Applicants for Second Session of Precedent-Setting U.S. Senior-Care Facility's School of Nursing 2Health News:Los Angeles Jewish Home's New Annenberg School of Nursing Seeks Applicants for Second Session of Precedent-Setting U.S. Senior-Care Facility's School of Nursing 3Health News:U of M researchers find cerebral malaria may be a major cause of brain injury in African children 2Health News:Skinvisible Offers 8 Hour Photostablity for Parsol 1789 2Health News:Skinvisible Offers 8 Hour Photostablity for Parsol 1789 3Health News:Fans Encourage Steve Bartman to Accept $25,000 Autograph Offer 2Health News:Hey fever! The surprise benefit of allergies 2
The Atria 6100 delivers the highest level of clinical performance while incorporating cutting-edge technology to streamline clinic workflow. It offers timely, high-quality, and accurate ECG results c...
... The new Guidant VASOVIEW® HemoPro™ ... deliver a new level of ... for both the saphenous vein ... cut-and-seal capability, it lets you ...
Patient Monitor...
...
Medicine Products: